News Heart trial success will give Xarelto edge Xarelto aces outcomes trial and could have edge over Boehringer and BMS rivals.
News Sanofi cholesterol drug can stay on US market - for now Sales of Praluent can continue during patent case appeal.
News OECD calls for 'rebalancing of power' in drug price negotiat... Health systems should fund more treatments for chronic diseases, says EFPIA
News Court bans US sales of Sanofi cholesterol drug Amgen looks to corner PCSK9 market after patent win.
News Novartis, BMS, Janssen unveil R&D deals Companies announce eye-catching R&D plans ahead of conference.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.